New drug cocktail aims to tackle tough sarcomas in young patients

NCT ID NCT06709495

Recruiting now Disease control Sponsor: David S Shulman, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called PEEL-224 combined with two standard chemotherapy drugs (vincristine and temozolomide) in adolescents and young adults whose sarcomas have returned or not responded to treatment. The trial has two phases: first, finding the safest dose, then checking how well the combination shrinks tumors. About 63 participants with Ewing sarcoma, desmoplastic small round cell tumors, or other sarcomas will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PEEL-224 (a topoisomerase 1 inhibitor) combined with vincristine and temozolomide
What this could lead to: If successful, this combination could offer a new treatment option for young people with sarcomas that have come back or not responded to standard therapy.
What could go wrong: This is an early-phase trial with a small number of participants, so the benefits are uncertain. The drugs may cause serious side effects, and the combination might not shrink tumors effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DESMOPLASTIC SMALL ROUND CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

desmoplastic small round cell tumor Ewing sarcoma osteosarcoma rhabdomyosarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DESMOPLASTIC SMALL ROUND CELL TUMOR OSTEOSARCOMA REFRACTORY SARCOMA RHABDOMYOSARCOMA SARCOMA SARCOMA, EWING

Contacts and locations

Locations

Boston Children's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
Brigham and Women's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.